{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33.3","upperLimit":"149","value":"68"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"125"}],"units":"Participants"}],"description":"Time from response to disease progression, measuring length of the response in those participants who responded.","dispersionType":"Full Range","groups":[{"description":"Imatinib mesylate 400 mg orally daily, HES participants start with 100 mg orally daily.","id":"OG000","title":"Imatinib Mesylate"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From response evaluation (first evaluation following 2 months therapy) to disease progression or death or until disease progression whichever occurs first, up to 12 years and 5 months","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"Months"}